TY - JOUR
T1 - VALIDATION OF ESOPHAGEAL GLOBAL SYMPTOM SEVERITY AS A PATIENT REPORTED OUTCOME FOR EVALUATION OF REFLUX SYMPTOMS
AU - Chan, Walter W.
AU - Schroeder, Matthew
AU - Richardson, Allyson
AU - Shah, Neemit
AU - Muftah, Mayssan
AU - Muftah, Samya
AU - Siboni, Stefano
AU - Sozzi, Marco
AU - Wong, Ming Wun
AU - Chen, Chien Lin
AU - Prakash Gyawali, C.
N1 - Publisher Copyright:
© 2025 by The American College of Gastroenterology.
PY - 2025
Y1 - 2025
N2 - Background:Visual analog scales (VAS) are simple, easy for patients to comprehend, and require limited translation. We evaluated the value of esophageal global symptom severity (GSS) measured using VAS in assessing initial reflux symptom burden as compared to other validated questionnaires, esophageal symptom burden, and outcome following reflux management.Methods:We analyzed pooled data from published historical cohorts of patients undergoing pH-impedance testing for reflux symptoms from three continents (North America, Europe, Asia). Univariate (Spearman correlation), multivariable (general linear regression) and receiver operating characteristic (ROC) analyses were performed to compare GSS with validated symptom instruments including gastroesophageal reflux disease questionnaire (GERDQ), GERD health-related quality of life (GERD-HRQL), and reflux symptom index (RSI), and metrics from pH-impedance monitoring per Lyon Consensus 2.0.Results:1296 patients (mean age 52.0 years, 61.9% female) were included, 937, 197, and 162 from North America, Europe, and Asia, respectively. GSS significantly correlated with GERDQ (R=0.455), GERD-HRQL (R=0.440), RSI (R=0.491), acid exposure time (AET) (R=0.158), and total reflux episodes (R=0.161) (p<0.0001 for each comparison). Mean GSS was higher with abnormal GERDQ, GERD-HRQL, and RSI, pathologic AET and conclusive GERD per Lyon Consensus (p<0.0001 each comparison). On ROC analyses, GSS was non-inferior to GERDQ, GERD-HRQL, and RSI in predicting pathologic AET and total reflux episodes, and conclusive GERD. Percentage improvement in GSS after antireflux treatment significantly correlated with change in GERDQ (R=0.536, p<0.0001) and treatment satisfaction (R=0.532 p=0.0002). On multivariable linear regression analyses, percentage change in GSS remained an independent predictor of both change in GERDQ (β=0.813, p<0.0001) and satisfaction with anti-reflux therapy (β=1.90, p=0.0006).Conclusions:GSS correlates with other validated reflux questionnaires and discriminates abnormal from normal reflux burden in patients with reflux symptoms. GSS change also reflects reflux treatment outcome and satisfaction. GSS is a useful addition to patient symptom assessment before and after GERD treatment.
AB - Background:Visual analog scales (VAS) are simple, easy for patients to comprehend, and require limited translation. We evaluated the value of esophageal global symptom severity (GSS) measured using VAS in assessing initial reflux symptom burden as compared to other validated questionnaires, esophageal symptom burden, and outcome following reflux management.Methods:We analyzed pooled data from published historical cohorts of patients undergoing pH-impedance testing for reflux symptoms from three continents (North America, Europe, Asia). Univariate (Spearman correlation), multivariable (general linear regression) and receiver operating characteristic (ROC) analyses were performed to compare GSS with validated symptom instruments including gastroesophageal reflux disease questionnaire (GERDQ), GERD health-related quality of life (GERD-HRQL), and reflux symptom index (RSI), and metrics from pH-impedance monitoring per Lyon Consensus 2.0.Results:1296 patients (mean age 52.0 years, 61.9% female) were included, 937, 197, and 162 from North America, Europe, and Asia, respectively. GSS significantly correlated with GERDQ (R=0.455), GERD-HRQL (R=0.440), RSI (R=0.491), acid exposure time (AET) (R=0.158), and total reflux episodes (R=0.161) (p<0.0001 for each comparison). Mean GSS was higher with abnormal GERDQ, GERD-HRQL, and RSI, pathologic AET and conclusive GERD per Lyon Consensus (p<0.0001 each comparison). On ROC analyses, GSS was non-inferior to GERDQ, GERD-HRQL, and RSI in predicting pathologic AET and total reflux episodes, and conclusive GERD. Percentage improvement in GSS after antireflux treatment significantly correlated with change in GERDQ (R=0.536, p<0.0001) and treatment satisfaction (R=0.532 p=0.0002). On multivariable linear regression analyses, percentage change in GSS remained an independent predictor of both change in GERDQ (β=0.813, p<0.0001) and satisfaction with anti-reflux therapy (β=1.90, p=0.0006).Conclusions:GSS correlates with other validated reflux questionnaires and discriminates abnormal from normal reflux burden in patients with reflux symptoms. GSS change also reflects reflux treatment outcome and satisfaction. GSS is a useful addition to patient symptom assessment before and after GERD treatment.
KW - gastroesophageal reflux disease
KW - pH-impedance monitoring
KW - proton pump inhibitor therapy
UR - http://www.scopus.com/inward/record.url?scp=105003954312&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000003499
DO - 10.14309/ajg.0000000000003499
M3 - Article
C2 - 40267269
AN - SCOPUS:105003954312
SN - 0002-9270
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
ER -